Merck KGaA (MRK: DE) and London-based Avillion have signed an agreement to collaborate on the development of the German pharma major’s anti interleukin (IL)-17 A/F Nanobody.
The immunology candidate will be developed and financed by Avillion through to regulatory submission. The drug is expected to begin Phase II tests in plaque psoriasis in 2017.
Merck will retain ownership and commercialization rights.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze